We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » ICER Takes U-Turn in Cost-Benefit Assessment for Two Migraine Drugs
ICER Takes U-Turn in Cost-Benefit Assessment for Two Migraine Drugs
The Institute for Clinical and Economic Review (ICER) has gone back on its initial value assessment for two of three acute migraine treatments, finding after a second look that the drugs may be cost-effective after all.